S
Semeia
AI-powered remote monitoring for chronic disease patients
About Semeia
Sêmeia is a French health-tech company founded in 2017 by Daniel Szeftel, Pierre Hornus (CEO), and Mathieu Godart (CTO). The company is headquartered in Paris, with its research and development team located in Toulouse, a move influenced by the region's strong healthcare and AI ecosystem. Sêmeia specializes in developing remote medical monitoring solutions for patients with serious or chronic illnesses. The company's core offering is MedicWise, a digital medical device platform that uses artificial intelligence to collect and analyze patient data in real-time. This allows healthcare professionals to monitor patients remotely, identify those at highest risk of complications, treatment cessation, or re-hospitalization, and intervene at the most critical moments. The system automates the collection of health data, including biological analysis, from various sources like connected devices and health insurance reimbursement data, presenting it on a dashboard for care teams. This process helps to save medical teams valuable time by reducing unnecessary hospital visits. Sêmeia's solutions are applied across several therapeutic areas, with a leading presence in nephrology through its NephroWise product. Other specialized applications include MentalWise (mental health), OncoWise (oncology), and ImmunoWise (autoimmune diseases), with plans to expand into stroke and diabetes care. The company serves clients such as industrial players in the health sector, scientific societies, and the French National Health Insurance (Assurance Maladie). The company has secured significant funding to support its growth. After an initial funding round in 2020, Sêmeia raised approximately €8 million ($8.28M) in a Series B round in December 2022. Key investors include Orange Ventures, Malakoff Humanis, and Banque des Territoires. In a strategic move to consolidate its market position, Sêmeia also acquired competitor Optim'Care in December 2022. Keywords: remote patient monitoring, artificial intelligence, health-tech, chronic disease management, predictive analytics, medical software, digital health, telehealth, data analytics, decision support, nephrology, oncology, mental health, MedicWise, risk prediction, healthcare data, patient follow-up, medical alerts, connected devices, clinical decision support
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Paris, France
- Employees
- 63
- Open positions
- 2
- Dealroom signal
- 83.7/100
- Industry
- Health
- Sub-industry
- Health Platform
- Sector
- Health Tech & Medtech, Remote Monitoring, Tech for Patients, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Digital Care, remote health monitoring, DT and LS, observatoire healthtech
- Technology
- Deep Tech
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Dec 2022
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Semeia.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | May 2026 | $23M | $92M | Orange Ventures · XAnge · Acton Capital · Mutuelles Impact | ↗ |
| EARLY VC✓Equity / VC | Dec 2022 | $8.8M | $35M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Semeia is 24K monthly website visits, up 196.3% over the last three months. Semeia's team grew 6.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
Life PlusEnables the prevention of the progressive weakening of the elderly population |
Paris, France | Operational | 57 | $3.3M | $13M |
DreemHeadband to improve your sleep every night |
Paris, France | Closed | |||
DiabeloopMedical device company for diabetes and closed-loop system and also develops disruptive technological innovations to automate the treatment of diabetes |
Grenoble, France | Operational | |||
ChronolifeBuilds predictive medical solutions to aid in diagnosis through a wireless, wearable technology |
Paris, France | Operational | |||
MoonaIs a revolutionary sleep device that actively improves sleep through temperature |
Levallois-Perret, France | Acquired | |||
OSO-AIImproving well-being and health through AI-based identification of human-related sounds |
Brest, France | Operational | |||
BioSerenityLeading global providers of remote diagnostic solutions |
Paris, France | Operational | |||
DiamparkOvercoming Parkinson's disease |
Chaville, France | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Orange Ventures
XAnge
Acton Capital
Mutuelles Impact
Banque des Territoires
Citizen Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Semeia on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Semeia’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








